Global, regional, and national burdens of chronic kidney disease attributable to high body mass index from 1990 to 2021, with future forecasts up to 2050: a systematic analysis for the global burden of disease study 2021
- PMID: 40703164
- PMCID: PMC12283729
- DOI: 10.3389/fpubh.2025.1612300
Global, regional, and national burdens of chronic kidney disease attributable to high body mass index from 1990 to 2021, with future forecasts up to 2050: a systematic analysis for the global burden of disease study 2021
Abstract
Background: High body mass index (BMI) is a major modifiable risk factor for the development and progression of chronic kidney disease (CKD) through established mechanisms, including glomerular hyperfiltration and metabolic dysfunction. This study aimed to characterize the global, regional, and national temporal trends in CKD attributable to BMI from 1990 to 2021 and forecast trends up to 2050.
Methods: Data were obtained from the Global Burden of Disease 2021 Study. Deaths and disability-adjusted life years (DALYs) for patients with CKD attributable to a high BMI were analyzed using age-standardized rates. The estimated annual percentage change was then calculated. Attribution was calculated as the product of the population-attributable fractions (PAFs) related to CKD deaths/DALYs and disease burden, with deaths/DALYs as the unit of measurement. Age-period cohort analysis was used to estimate the age, period, and cohort effects. Bayesian age-period-cohort modeling was used to predict the burden of CKD associated with high BMI from 2021 to 2050.
Results: From 1990 to 2021, the burden of CKD attributable to BMI showed an increasing trend. Age-standardized death and DALY rates increased in all Sociodemographic Index regions from 1990 to 2021. At the national level, most countries have exhibited an increase in burden from 1990 to 2021. Among females, the 85-89 age group had the highest number of deaths (28,478), whereas among males, it was the 70-74 age group (25,270). Globally, high BMI is a risk factor for CKD, contributing to 27.3% of deaths. With respect to the age effect, deaths from CKD attributable to high BMI increased with age. The burden of CKD attributable to high BMI generally increases from 2021 to 2050.
Conclusion: The burden of CKD attributable to high BMI increased significantly between 1990 and 2021. The growing global burden demands urgent and mechanistically informed health interventions that target the complex pathophysiology of obesity-related kidney diseases.
Keywords: BAPC model; age-period-cohort; chronic kidney disease; global burden of disease; high body mass index.
Copyright © 2025 Ying, Lan, Zhou, Li, Sheng and Huang.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures








Similar articles
-
The global burden of chronic kidney disease due to glomerulonephritis: trends and predictions.Int Urol Nephrol. 2025 Aug;57(8):2613-2624. doi: 10.1007/s11255-025-04440-2. Epub 2025 Mar 5. Int Urol Nephrol. 2025. PMID: 40045051 Free PMC article.
-
Global trends of chronic kidney disease from 1990 to 2021: a systematic analysis for the global burden of disease study 2021.BMC Nephrol. 2025 Jul 14;26(1):385. doi: 10.1186/s12882-025-04309-7. BMC Nephrol. 2025. PMID: 40660180 Free PMC article.
-
Global, regional, and national trends in the epidemiology of aortic aneurysms among women of childbearing age, 1990-2021, with predictions through 2036.BMC Public Health. 2025 Jul 2;25(1):2224. doi: 10.1186/s12889-025-23502-9. BMC Public Health. 2025. PMID: 40604749 Free PMC article.
-
Global burden and risk factors of musculoskeletal disorders among adolescents and young adults in 204 countries and territories, 1990-2019.Autoimmun Rev. 2023 Aug;22(8):103361. doi: 10.1016/j.autrev.2023.103361. Epub 2023 May 23. Autoimmun Rev. 2023. PMID: 37230312 Review.
-
Early referral strategies for management of people with markers of renal disease: a systematic review of the evidence of clinical effectiveness, cost-effectiveness and economic analysis.Health Technol Assess. 2010 Apr;14(21):1-184. doi: 10.3310/hta14210. Health Technol Assess. 2010. PMID: 20441712
References
-
- Asmelash D, Chane E, Desalegn G, Assefa S, Aynalem GL, Fasil A. Knowledge and practices towards prevention and early detection of chronic kidney disease and associated factors among hypertensive patients in Gondar town, north West Ethiopia. Int J Hypertens. (2020) 2020:1–8. doi: 10.1155/2020/2860143, PMID: - DOI - PMC - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical